A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma Meeting Abstract

  


Authors: Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Das, J. P.; Lezcano, C.; Nair, S.; Lochrin, S. E.; Chen, M. F.; Panageas, K.; Postow, M. A.
Abstract Title: A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma
Meeting Title: 2024 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 42
Issue: 16 Suppl.
Meeting Dates: 2024 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2024-06-01
Language: English
ACCESSION: WOS:001275557406403
PROVIDER: wos
DOI: 10.1200/JCO.2024.42.16_suppl.TPS9605
Notes: Meeting Abstract: TPS9605 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    362 Postow
  2. Katherine S Panageas
    512 Panageas
  3. Alexander Noor Shoushtari
    244 Shoushtari
  4. Parisa Momtaz
    54 Momtaz
  5. Maria Cecilia Lezcano Lopez
    41 Lezcano Lopez
  6. Jeeban Paul Das
    43 Das
  7. James William Smithy
    28 Smithy
  8. Monica Chen
    31 Chen
  9. Sarah Elizabeth Lochrin
    6 Lochrin
Related MSK Work